HIGHLIGHTS

3299 AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative

3368 Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletic, Markus Ringnér, Johan R. Lillegaard, Åke Borg, and Per Eystein Lønnø

3378 A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas
Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoriadis, Alan Ashworth, Rui M. Reis, David W. Ellison, Safa Al-Sarraj, Darren Hargrave, and Chris Jones

MOLECULAR PATHWAYS

3329 Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response
Christine A. Pratilas and David B. Solit

3356 Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer
Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

3385 The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment
Ivor Caro and Jennifer A. Low

HUMAN CANCER BIOLOGY

3340 BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood
Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich G. Weier, Krzysztof P. Bielawska, and Burkhard Brandt

3399 Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy
Darya Alizadeh, Liley Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnam Badie

The Journal of Clinical and Translational Research
Role of Type-1 IFNs in Antiglioma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans

Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
Wei Zhang, Xiao-Dong Zhu, Hui-Chuan Sun, Yu-Quan Xiong, Peng-Yuan Zhuang, Hua-Xiang Xu, Ling-Qun Kong, Lu Wang, Wei-Zhong Wu, and Zhao-You Tang

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies
Nienke A. de Vries, Sophia W. Bruggeman, Daniëlle Hulsman, Hilda I. de Vries, John Zevenhoven, Tessa Buckle, Bob C. Hamans, William P. Leenders, Jos H. Beijnen, Maarten van Lohuizen, Anton J.M. Berns, and Olaf van Tellingen

Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer

Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non–Small Cell Lung Cancer
Erich C. Farlow, Kalpa Patel, Sanjib Basu, Bao-Shiang Lee, Anthony W. Kim, John S. Coon, L. Penfield Faber, Philip Bonomi, Michael J. Liptay, and Jeffrey A. Borgia

Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR
Kimberly Laskie Ostrow, Mohammad O. Hoque, Myriam Loyo, Marianna Brait, Alissa Greenberg, Jill M. Siegfried, Jennifer R. Grandis, Autumn Gaither Davis, William L. Bigbee, William Rom, and David Sidransky

Diverse Associations between ESRI Polymorphism and Breast Cancer Development and Progression
Shian-ling Ding, Jyh-Cherng Yu, Shou-Tung Chen, Gao-Cheng Hsu, Huan-Ming Hsu, Jar-Yi Ho, Yu Hsin Lin, Chien-Ching Chang, Cathy S.I. Fann, Chun-Wen Cheng, Pei-Ei Wu, and Chen-Yang Shen

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divisi Khaira, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, and Susan M. Domchek

Results from a Phase I Clinical Study of the Novel II-Key/HER-2/neu (776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
Sonia A. Perez, Nikaletta L. Kallinteris, Stratos Bisias, Panagiotis K. Tzonis, Katerina Georgakopoulou, Marihougha Varla-Leftherioti, Michael Papamichail, Anastasios Thanos, Eric von Hofe, and Constantin N. Baxevanis

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

CANCER THERAPY: CLINICAL

IMAGING, DIAGNOSIS, PROGNOSIS
ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into $\text{LoxP}$-conditional $\text{p53}$(or $\text{pten}$);$\text{Ink4a}$/\text{Arf}$;K-Ras^{v12}$;LucR mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.